Echo IQ (ASX:EIQ) said that it is working collaboratively with reimbursement advisers and other key stakeholders to resubmit its application for a category III current procedural technology (CPT) code for EchoSolv AS in the US for the next CPT editorial panel cycle, according to a Wednesday Australian bourse filing.
The firm's application for a category III CPT code was deemed unsuccessful at the most recent CPT editorial panel meeting, the filing said. It is engaging with the American Medical Association regarding the rationale for this decision.
The company said it will incorporate the feedback and guidance provided by the association into its revised application. It will resubmit before the next deadline of June 11, allowing it to present its application in September.
The active use of EchoSolv AS across existing sites in the US will not be interrupted due to this development, the filing noted.
Echo IQ's shares jumped nearly 13% in recent trading on Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。